Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.

We conducted a phase I study of irinotecan (CPT-11) and etoposide (VP-16) given sequentially to untreated patients with metastatic non-small-cell lung cancer. Arm A: CPT-11 was given over 90 min on days 1-3 and VP-16 was given over 60 min on days 4-6. Arm B: VP-16 was given on days 1-3 and CPT-11 on...

Descripción completa

Detalles Bibliográficos
Autores principales: Ando, M., Eguchi, K., Shinkai, T., Tamura, T., Ohe, Y., Yamamoto, N., Kurata, T., Kasai, T., Ohmatsu, H., Kubota, K., Sekine, I., Hojo, N., Matsumoto, T., Kodama, T., Kakinuma, R., Nishiwaki, Y., Saijo, N.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228187/
https://www.ncbi.nlm.nih.gov/pubmed/9400948

Ejemplares similares

Ejemplares similares